Alzheimer's Disease - Diagnosis, Disease Modification and Prevention Key to Growing Market

Questions: Discounts, Updates etc.

Price: $11,400.00

Publication Date: 2004-07-01

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Over the next ten years the Alzheimer's disease market will become increasingly competitive as potentially disease modifying drugs vie for approval. Companies will need to scrutinize their plans to ensure implementation of appropriate launch strategies, achieving clear positioning and differentiation in a changing environment. What is right for launch in 2005 may not be effective at a later date.


Scope

  • Epidemiology of Alzheimer's Disease across the 7 major markets, as well as analysis of the main unmet needs in the current treatment of the disease
  • Overview of drugs in Phase III, II, I and pre-clinical development, plus analysis of key companies involved in the R&D pipeline: Pfizer, Lilly & Sanofi
  • Comprehensive analysis of key late-stage products phenserine, Alzhemed, PBT-1 and Colostrinin, with Datamonitor forecasts of drug revenues to 2014
  • Insight into innovative early stage products, including vaccines, as well as analysis of key research impacts concerning beta-amyloid


    • Report Highlights
    Marketed products only provide temporary partial symptomatic relief: disease modification and prevention are major unmet needs. Opinion leaders consider phenserine (Axonyx) and Alzhemed (Neurochem) to have potential for successful disease modification which could challenge Aricept's market domination if supported by sufficient marketing strength.

    Physicians and sections of the pharmaceutical industry are searching for options to prevent Alzheimer's disease. The large number of mechanisms contributing to the etiology and progression of the disorder add complications. There is substantial opportunity but the industry will need to carefully consider the challenges of a prophylactic market.

    An increasing focus on disease prevention and early identification highlights a need for simple diagnostic tools and biological markers. Identification of 'at risk' and early clinical groups would aid trial design and assist patient segmentation and product positioning strategies, key factors as more players enter the market


    Reasons to Purchase

  • Enhance your sales forecasting ability and future product positioning through identification of market drivers and key competitors
  • Optimize your knowledge of company strategies in the AD market
  • Identify areas of the market that are not being targeted by competitors and gain an objective view of potential in-licensing opportunities

    • Table of Contents

    Other users found this report page using the following search terms: neuroprotection neurodegenerative alzheimers alzheimers disease modification market unmet alzhemed diagnosis alzheimer epidemiology management

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.